PROTECT Me: Assessing Antenatal Maternal Melatonin Supplementation in Fetal Growth Restriction to Improve Neurodevelopmental Outcomes. Fetal growth restriction (FGR) complicates over 30 million pregnancies globally. It significantly increases the risk of stillbirth, preterm birth and is a recognised causal pathway to the neurodevelopmental injury underlying subsequent cognitive and behavioural impairment and cerebral palsy. This is the first phase III randomised, placebo-controlled trial assessing the use of melatonin, a cheap and widely available supplement, in pregnancies complicated by early onset FGR to protect the unborn fetal brain and improve subsequent neurodevelopmental outcomes.
Sites: Auckland (more New Zealand sites are currently in set up)
ANZCTR number: ACTRN12617001515381